You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2024

CLINICAL TRIALS PROFILE FOR TOLVAPTAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for tolvaptan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00043758 ↗ Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 2 2002-07-01 The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)
NCT00043771 ↗ Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 2 2002-05-01 Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
NCT00071331 ↗ EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2003-09-01 The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
NCT00072683 ↗ "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia Completed Otsuka Pharmaceutical Co., Ltd. Phase 3 2003-04-01 This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tolvaptan

Condition Name

Condition Name for tolvaptan
Intervention Trials
Hyponatremia 17
Autosomal Dominant Polycystic Kidney Disease 11
Heart Failure 8
Congestive Heart Failure 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for tolvaptan
Intervention Trials
Polycystic Kidney Diseases 28
Kidney Diseases 27
Hyponatremia 26
Polycystic Kidney, Autosomal Dominant 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for tolvaptan

Trials by Country

Trials by Country for tolvaptan
Location Trials
United States 368
United Kingdom 43
Germany 26
Canada 23
Australia 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for tolvaptan
Location Trials
Pennsylvania 17
Georgia 17
Ohio 16
California 16
North Carolina 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for tolvaptan

Clinical Trial Phase

Clinical Trial Phase for tolvaptan
Clinical Trial Phase Trials
Phase 4 19
Phase 3 34
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for tolvaptan
Clinical Trial Phase Trials
Completed 54
Not yet recruiting 10
Terminated 9
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tolvaptan

Sponsor Name

Sponsor Name for tolvaptan
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 26
Otsuka Pharmaceutical Co., Ltd. 14
Otsuka America Pharmaceutical 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for tolvaptan
Sponsor Trials
Other 83
Industry 68
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.